Skip to main content
MedPathMedPath Home
Clinical Trials/SLCTR/2018/035
SLCTR/2018/035
Recruiting
Phase 2

Pharmacotherapeutic and physicochemical evaluation of Ayabirungarajakarpam – A poly herbometallic drug for Paandu –Anaemia

Dr. V. Elango0 sites216 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsAnaemia

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Anaemia
Sponsor
Dr. V. Elango
Enrollment
216
Status
Recruiting
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Interventional

Investigators

Sponsor
Dr. V. Elango

Eligibility Criteria

Inclusion Criteria

  • •Age – 19 \-60 years
  • •Male and female
  • •With the following cardinal signs of iron deficiency anaemia
  • •2\. Palpitation
  • •3\. Extreame fatigue
  • •4\. Exertional dyspnoea
  • •With a hemoglobin value of 7 – 11g/dL
  • •With a serum ferritin level of\<12 micrograms/L

Exclusion Criteria

  • •Patients with
  • •\- Haemoglobin below7g/dL
  • •\- Serum ferritin below 8 micrograms/L
  • •\- Diagnosed with any other type of anaemia other than Iron deficiency anaemia.
  • •Patients with the following complications
  • •\-Cardiac diseases
  • •\-Renal diseases
  • •\-Liver diseases
  • •\-Diabetes mellitus
  • •\-Hypertension

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
A study to investigate the effect of Nagapheni (Optunia elatior Mill.) in the treatment of anemia.Health Condition 1: null- Patients selected on the basis of the classical symptoms of Pandu(anaemia) and Level of Hb is low to normal value
CTRI/2015/02/005547Institute for post gradute teaching and research in Ayurevda gujarat ayurveda university jamnagar60
Not yet recruiting
Not Applicable
A study on the pharmacokinetics and pharmacodynamics of remimazolam during total intravenous anesthesia with remifentanilNot Applicable
KCT0007066Inje University Busan Paik Hospital15
Active, not recruiting
Not Applicable
Evaluation of the reduction in heart rate, of the quantity of drug in the plasma and of the safety after different ascending oral doses of the active substance or a placebo in heart failure patients with a reduction of left ventricular ejection fraction (i.e. thequantity of blood the heart is able to eject in the body at each heart beat).
EUCTR2013-003000-39-EEInstitut de Recherches Internationales Servier125
Active, not recruiting
Not Applicable
Evaluation of the reduction in heart rate, of the quantity of drug in the plasma and of the safety after different ascending oral doses of the active substance or a placebo in heart failure patients with a reduction of left ventricular ejection fraction (i.e. thequantity of blood the heart is able to eject in the body at each heart beat).
EUCTR2013-003000-39-HUInstitut de Recherches Internationales Servier200
Active, not recruiting
Not Applicable
Evaluation of the reduction in heart rate, of the quantity of drug in the plasma and of the safety after different ascending oral doses of the active substance or a placebo in heart failure patients with a reduction of left ventricular ejection fraction (i.e. thequantity of blood the heart is able to eject in the body at each heart beat).Patients with chronic heart failure and left ventricular systolicdysfunctionMedDRA version: 17.1Level: LLTClassification code 10007648Term: Cardiovascular disease, unspecifiedSystem Organ Class: 100000004849Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
EUCTR2013-003000-39-BEInstitut de Recherches Internationales Servier125